汇仁肾宝品牌怎么样 申请店铺

我要投票 汇仁肾宝在成人用品行业中的票数:398 更新时间:2025-08-22
汇仁肾宝是哪个国家的品牌?「汇仁肾宝」是 汇仁集团有限公司 旗下著名品牌。该品牌发源于江西省南昌市,由创始人陈董在1996年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力汇仁肾宝品牌出海!将品牌入驻外推网,定制汇仁肾宝品牌推广信息,可以显著提高汇仁肾宝产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

汇仁肾宝怎么样

江西汇仁药业股份有限公司,是一家专注于研发、生产、销售调理滋补类OTC中药的工业企业。公司总部位于南昌小蓝经济技术开区,汇仁药业秉承“仁者爱人”的核心理念,走出了一条独具特色的健康产业发展之路,企业综合经济实力迅速提升。

公司主要从事片剂、胶囊剂、颗粒剂、口服液、合剂、丸剂等调理滋补类OTC中药的生产和销售。主要产品有中药“肾宝片”、女金胶囊、解毒痤疮丸等核心产品。

公司坚持振兴民族医药和自主创新的发展观念,投巨资在中国药谷——上海张江高科技园区建设企业研发中心,中心拥有向全国开放的大规模中试平台和一大批国际精良的仪器设施。先后引进了博士生导师、博士后、博士等二十多位高层次医药科研人才并建立了博士后工作站。公司自成立以来注重投入研发、技术和管理上的创新,完成了150余个药品(项目)的开发,取得了100余个新药证书或生产批文。

公司研发的产品“肾宝片”、“解毒痤疮丸”、“女金胶囊”等在投产上市后已经取得了社会效益和经济效益。多项具有独立自主知识产权的产品正在加紧研制阶段,例如中药六类新药川红活血胶囊、颐神养脑胶囊等研究项目,此批产品的成功上市标志着汇仁药业自主研发水平达到了一定的高度,进一步提升了企业产品的技术含量、技术附加值、市场占有率和品牌价值。

结合企业发展方向,汇仁药业将按照新产品研发技术要求,建成具有国内前沿水平的新产品研发中心。依据公司战略规划,将围绕中药调理滋补类OTC药品、保健品和药食同源食品开展研究工作。



Jiangxi Huiren Pharmaceutical Co., Ltd. is an industrial enterprise focusing on R & D, production and sales of OTC tonic traditional Chinese medicine. Headquartered in Xiaolan economic and Technological Development Zone, Nanchang, Huiren Pharmaceutical Co., Ltd. adheres to the core concept of "benevolent people love each other" and embarks on a unique road of healthy industry development, with its comprehensive economic strength rapidly improved. The company is mainly engaged in the production and sales of OTC traditional Chinese medicine such as tablet, capsule, granule, oral liquid, mixture, pill, etc. The main products are "Shenbao tablet", Nujin capsule, Jiedu acne pill and other core products. The company adheres to the development concept of revitalizing national medicine and independent innovation, and invests heavily in the construction of enterprise R & D center in Shanghai Zhangjiang High Tech Park, China Pharmaceutical valley. The center has a large-scale pilot test platform open to the whole country and a large number of international excellent instruments and facilities. More than 20 high-level medical research talents, including doctoral supervisor, postdoctoral and doctor, have been introduced and a postdoctoral workstation has been established. Since its establishment, the company has focused on innovation in R & D, technology and management, completed the development of more than 150 drugs (projects), and obtained more than 100 new drug certificates or production approvals. The products "Shenbao tablet", "Jiedu acne pill" and "Nujin capsule" researched and developed by the company have achieved social and economic benefits after being put into production and put on the market. A number of products with independent intellectual property rights are stepping up the research and development stage, such as Chuanhong Huoxue Capsule, Yishen Yangnao capsule and other research projects. The successful listing of these products marks that Huiren pharmaceutical has reached a certain level of independent research and development, further improving the technical content, technical added value, market share and brand value of the enterprise's products. In combination with the development direction of the enterprise, Huiren pharmaceutical will establish a new product R & D center with domestic cutting-edge level in accordance with the technical requirements of new product R & D. According to the company's strategic plan, research work will be carried out around TCM tonic OTC drugs, health care products and medicine food homologous food.

本文链接: https://brand.waitui.com/310e607cb.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

“应世生物”完成超3400万美元C轮融资

36氪获悉,据昆仑资本官微,近日,聚焦实体瘤耐药治疗的创新药研发公司“应世生物”宣布完成超3400万美元的C轮融资,本轮融资由复健资本领投,比邻星创投、澄翔资本、昆仑资本投资,老股东恩然创投继续追加投资。

2小时前

法国液化空气集团将以28.5亿欧元的企业价值收购Dig Airgas

法国液化空气集团(Air Liquide)将以28.5亿欧元的企业价值收购Dig Airgas。(财联社)

2小时前

传东方甄选前CEO孙东旭将离职 官方暂无回应

8月22日午间消息,据媒体报道,前东方甄选CEO孙东旭目前已经进入休假状态,可能将在近期离职。对此消息,东方甄选官方暂无回应。(新浪科技)

2小时前

沪指涨幅扩大至1%,刷新2015年8月20日以来新高

36氪获悉,沪指涨幅扩大至1%,刷新2015年8月20日以来新高。

2小时前

沪深京三市成交额连续第8个交易日突破2万亿

36氪获悉,沪深京三市成交额连续第8个交易日突破2万亿,较上日此时放量超600亿。

2小时前

本页详细列出关于汇仁肾宝的品牌信息,含品牌所属公司介绍,汇仁肾宝所处行业的品牌地位及优势。
咨询